Replies to post #5958 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

Always nice to see something like this, again:

At the day 90 assessment, 82% of target lesions demonstrated a response after only a single cycle of treatment, with 47% being complete responses. Target lesions demonstrated a 68% durable response rate (= 6 months) at 90 days.

...

Because of the encouraging results seen for this approach in melanoma, a phase II study was begun in Merkel cell carcinoma, and results were similar, said Dr. Bhatia, who lectured on emerging therapies for Merkel cell carcinoma at the meeting.

He said complete responses were observed within weeks of injections, and noninjected lesions elsewhere on the body also regressed within weeks or months. Increased intratumoral CD8-positive infiltration was observed in 50% of patients.

“This suggests that we are getting a successful immune response,” Dr. Bhatia said. “The big advantage of this approach is its localized delivery without the production of systemic side effects.”

I guess Dr. Bhatia let the cat out of the bag with regard to phase II positive results.
$ONCS